Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
Phase 3
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 276
- Registration Number
- NCT00378014
- Locations
- 🇨🇭
Novartis Investigative Site, Zurich, Switzerland
Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation
Phase 4
Completed
- Conditions
- Disorder Related to Cardiac Transplantation
- Interventions
- Drug: Mycophenolic acid (MPA)/azathioprine (AZA)Drug: Calcineurin inhibitors (CNI)Drug: Steroids
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 282
- Registration Number
- NCT00377962
- Locations
- 🇸🇪
Novartis Investigative Site, Lund, Sweden
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Phase 4
Completed
- Conditions
- Acromegaly
- Interventions
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00376064
- Locations
- 🇩🇪
Novartis Investigative Site, Wurzburg, Germany
Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 168
- Registration Number
- NCT00375752
- Locations
- 🇩🇪
Novartis Investigative Site, Ulm, Germany
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT00375505
- Locations
- 🇩🇪
Novartis Investigative Site, Marburg, Germany
Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT00375648
- Locations
- 🇫🇷
Novartis Investigative Site, Monpellier, France
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 430
- Registration Number
- NCT00375427
- Locations
- 🇮🇹
Novartis Investigative Site, Forlì, Italy
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT00372697
- Locations
- 🇮🇹
Novartis Investigative Site, Brescia, Italy
Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT00372476
- Locations
- 🇩🇪
Novartis Investigative Site, Kiel, Germany
SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus
Phase 4
Completed
- Conditions
- Renal Transplanted Recipients
- Interventions
- Drug: Methylprednisone/prednisone
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2013-08-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT00371826
- Locations
- 🇦🇺
Westmead Hospital, NSW, Australia
🇦🇺Sir Charles Gairdner Hospital, WA, Australia
🇦🇺Monash Medical Centre, Sale, Australia
© Copyright 2025. All Rights Reserved by MedPath